Hematology: Coagulation Problems

Sandor S. Shapiro; Stephen E.F. Spurgeon

doi:10.1016/B978-012433901-9/50045-4

Hematology: Coagulation Problems

Sandor S. Shapiro, Stephen E.F. Spurgeon

Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Scopus citations

Abstract

Lupus anticoagulants (LACs) are immunoglobulins that interfere with in vitro phospholipid-dependent coagulation tests. Initially recognized in the context of systemic lupus erythematosus (SLE), LACs are now known to occur frequently in patients with other disorders, as well as in individuals with no apparent underlying disease. It is now recognized that LACs and anti-cardiolipin antibodies (ACAs) are separate entities, but both are members of a diverse group of immunoglobulins that bind to phospholipid-bound proteins including, but not limited to, β2-glycoprotein-I (β2GPI) and prothrombin. LACs and ACAs are both associated with a high risk of arterial and venous thromboembolicevents, although the mechanism of this thrombotic risk is still unknown. In this chapter the term “anti-phospholipid antibody (APL)” is used to denote the presence of a LAC and/or ACA. The chapter discusses the diagnosis of LACs, the possible thrombotic mechanisms associated with APLs, and the treatment of thrombosis in patients with APLs.

Original language	English (US)
Title of host publication	Systemic Lupus Erythematosus, Fourth Edition
Publisher	Elsevier
Pages	1139-1160
Number of pages	22
ISBN (Electronic)	9780124339019
DOIs	https://doi.org/10.1016/B978-012433901-9/50045-4
State	Published - Jan 1 2004
Externally published	Yes

ASJC Scopus subject areas

General Medicine
General Immunology and Microbiology

Access to Document

10.1016/B978-012433901-9/50045-4

Cite this

@inbook{f72eca4efdae4f0e8910a061859d4075,

title = "Hematology: Coagulation Problems",

abstract = "Lupus anticoagulants (LACs) are immunoglobulins that interfere with in vitro phospholipid-dependent coagulation tests. Initially recognized in the context of systemic lupus erythematosus (SLE), LACs are now known to occur frequently in patients with other disorders, as well as in individuals with no apparent underlying disease. It is now recognized that LACs and anti-cardiolipin antibodies (ACAs) are separate entities, but both are members of a diverse group of immunoglobulins that bind to phospholipid-bound proteins including, but not limited to, β2-glycoprotein-I (β2GPI) and prothrombin. LACs and ACAs are both associated with a high risk of arterial and venous thromboembolicevents, although the mechanism of this thrombotic risk is still unknown. In this chapter the term “anti-phospholipid antibody (APL)” is used to denote the presence of a LAC and/or ACA. The chapter discusses the diagnosis of LACs, the possible thrombotic mechanisms associated with APLs, and the treatment of thrombosis in patients with APLs.",

author = "Shapiro, {Sandor S.} and Spurgeon, {Stephen E.F.}",

year = "2004",

month = jan,

day = "1",

doi = "10.1016/B978-012433901-9/50045-4",

language = "English (US)",

pages = "1139--1160",

booktitle = "Systemic Lupus Erythematosus, Fourth Edition",

publisher = "Elsevier",

}

TY - CHAP

T1 - Hematology

T2 - Coagulation Problems

AU - Shapiro, Sandor S.

AU - Spurgeon, Stephen E.F.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Lupus anticoagulants (LACs) are immunoglobulins that interfere with in vitro phospholipid-dependent coagulation tests. Initially recognized in the context of systemic lupus erythematosus (SLE), LACs are now known to occur frequently in patients with other disorders, as well as in individuals with no apparent underlying disease. It is now recognized that LACs and anti-cardiolipin antibodies (ACAs) are separate entities, but both are members of a diverse group of immunoglobulins that bind to phospholipid-bound proteins including, but not limited to, β2-glycoprotein-I (β2GPI) and prothrombin. LACs and ACAs are both associated with a high risk of arterial and venous thromboembolicevents, although the mechanism of this thrombotic risk is still unknown. In this chapter the term “anti-phospholipid antibody (APL)” is used to denote the presence of a LAC and/or ACA. The chapter discusses the diagnosis of LACs, the possible thrombotic mechanisms associated with APLs, and the treatment of thrombosis in patients with APLs.

AB - Lupus anticoagulants (LACs) are immunoglobulins that interfere with in vitro phospholipid-dependent coagulation tests. Initially recognized in the context of systemic lupus erythematosus (SLE), LACs are now known to occur frequently in patients with other disorders, as well as in individuals with no apparent underlying disease. It is now recognized that LACs and anti-cardiolipin antibodies (ACAs) are separate entities, but both are members of a diverse group of immunoglobulins that bind to phospholipid-bound proteins including, but not limited to, β2-glycoprotein-I (β2GPI) and prothrombin. LACs and ACAs are both associated with a high risk of arterial and venous thromboembolicevents, although the mechanism of this thrombotic risk is still unknown. In this chapter the term “anti-phospholipid antibody (APL)” is used to denote the presence of a LAC and/or ACA. The chapter discusses the diagnosis of LACs, the possible thrombotic mechanisms associated with APLs, and the treatment of thrombosis in patients with APLs.

UR - http://www.scopus.com/inward/record.url?scp=59849123263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59849123263&partnerID=8YFLogxK

U2 - 10.1016/B978-012433901-9/50045-4

DO - 10.1016/B978-012433901-9/50045-4

M3 - Chapter

AN - SCOPUS:59849123263

SP - 1139

EP - 1160

BT - Systemic Lupus Erythematosus, Fourth Edition

PB - Elsevier

ER -

Hematology: Coagulation Problems

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this